Abstract Misuse of prescribed and over the counter (OTC) codeine containing medicines is an increasing public health concern in recent times. Studies have called for low threshold treatment services for individuals experiencing codeine dependence using buprenorphine naloxone therapy. We present a scoping review of clinical case presentation literature on the use of buprenorphine-naloxone in the treatment of codeine dependence. Seven records (four single case studies and three case series) on codeine dependence treated with buprenorphine-naloxone were included. Five themes emerged following a review of the cases for the treatment of codeine dependence with buprenorphine-naloxone. They are: (1) Patient Profiles; (2) History of Codeine Misuse; (3) Medical Problems; (4) Use of Other Substances; and (5) Buprenorphine-naloxone in the treatment of Codeine Dependence. The review highlights the complexities of patients with regards to pain, psychiatric illness, poly substance use and iatrogenic dependence, with findings encouraging in terms of patient stabilisation and recovery.
short acting, weak to mid-range opiate (Tremlett et al. 2010 ) used for the symptomatic relief of mild to moderate pain or cough (Derry et al. 2013) . OTC formulations contain varying strengths of codeine in different countries . Misuse of codeine combination analgesic products (ibuprofen or acetaminophen) is increasing where available OTC (McAvoy et al. 2011) . Stronger regulatory responses to tackle misuse have been debated (Tobin et al. 2013) .
Typical side effects on use include altered perceptions and emotional responses to pain, euphoria and sedation, and the development of tolerance within relatively short timeframes on repeated use Frei et al. 2010; Kelly and Madadi 2012; Babalonis et al. 2013) . Increased use of codeine stimulates neuro-adaptation and dependence McAvoy et al. 2011) , with withdrawal symptomatology including preoccupation with seeking and taking codeine, craving and lack of control over use . The variability of genetic metabolic response contributes to risk of misuse Ingelman-Sundberg et al. 2007; Frei et al. 2010; Nielsen et al. 2010) . Increases in mortality are reported (Pilgrim et al. 2013; Handley and Flanagan 2014) , with particular adverse health consequences such as hypokalaemia, gastrointestinal haemorrhage, acute haemorrhagic necrotizing pancreatitis and inflammatory bowel conditions centring on the misuse of combination analgesics containing codeine (Lambert and Close 2005; Dutch 2008; Evans et al. 2010; Ernest et al. 2010; Frei et al. 2010; Ng et al. 2011; Van Hout et al. 2014) . Psychiatric co-morbidity such as anxiety, depression and dysphoria is also reported Dobbin and Tobin 2008; Frei et al. 2010; Nielsen et al. 2010; McAvoy et al. 2011; Manchia et al. 2013) .
Treatment uptake for OTC codeine dependence is increasing in Australia, South Africa and the UK (Myers et al. 2003; McDonough 2011; Stannard 2013; Nielsen et al. 2015a) . Recent qualitative studies have explored patient experiences of misuse and dependence in Ireland, the UK, South Africa and Australia (Nielsen et al. , 2013 Cooper 2011 Cooper , 2013 Van Hout 2015; Van Hout et al. 2015a, b) . Recent studies have called for enhanced targeted design of appropriate treatment services for individuals experiencing codeine dependence (Nielsen et al. 2015b; Marr and Hill 2015) as these individuals are different to other opioid dependent patients Nielsen et al. 2015c) , by virtue of their lack of recognition of problematic use, perceptions around drug addiction and lack of self-identification, and experiences of stigma relating to mainstream drug addiction services Reed et al. 2011; Van Hout et al. 2015a , b Kean 2015 . Despite these differences, there is a limited evidence base to underpin best practice guidelines for the treatment of this form of opioid dependence (Cooper 2013; Conroy and Hill 2014; Hard 2014) , with approaches generally centring on substitution treatment (National Institute for Health and Clinical Excellence 2007) . One such form of pharmacological treatment of opioid dependence is buprenorphine -naloxone, commonly used in low threshold treatment of heroin dependence, and which is an effective opioid agonist treatment for prescription and OTC opioid analgesic dependence (Sigmon et al. 2009; Weiss et al. 2011) . It is reported to benefit patients with codeine dependence (Department of Health (England) and the developed administrations 2007; Stannard 2013; The Royal College of General Practitioners 2014a, b, c; Nielsen et al. 2015a; Van Hout et al. 2015a, b) . There is an increasing evidence base of case studies implicating use of this therapeutic agent in successful treatment outcomes (Hard 2014; Conroy and Hill 2014; Kean 2015; Marr and Hill 2015; Van Hout et al. 2015c ). Decisions to treat using buprenorphine naloxone centre on its safety profile (ceiling effect on respiratory depression and lower abuse potential), in comparison to other common opioid agonist treatments (ie methadone), reduced symptoms of withdrawal on cessation of use, lack of association with QT prolongation, and most importantly for these patients is the ability to continue with employment and enhanced social functioning, attributed to clarity of thought and the dislike of the sedating effect of methadone (Conroy and Hill 2014; New Zealand Ministry of Health 2014; Fiellin et al. 2014; Hard 2014) . Additionally, with buprenorphinenaloxone patient transfer into opioid agonist treatment is easier, with stabilisation achieved relatively easily, and with cessation relatively easily within short timeframes. In contrast, safe titration of methadone dose takes longer, and with high dose methadone posing an overdose risk. With this in mind, we therefore present a scoping review of available case presentation literature on the use of buprenorphine-naloxone in the treatment of codeine dependence.
Methods
Scoping review methods are emerging as an increasingly popular and accepted approach across many different disciplines in recent times (Anderson et al. 2008; Arskey and O'Malley 2005; Daudt et al. 2013; Levac et al. 2010; Pham et al. 2014) . A scoping review is generally used to determine the significance of a full systematic review, summarise and disseminate findings of the research, and identify gaps in the current literature (Arskey and O'Malley 2005; Levac et al. 2010) .
For the purpose of this study, Daudt et al.'s (2013:8) scoping review definition was employed. They define a scoping review as a form of research synthesis with objectives to Bmap the literature on a particular topic or research area and provide an opportunity to identify key concepts; gaps in the research; and types and sources of evidence to inform practice, policymaking, and research^. The decision to undertake a scoping review was due to this type of review being advantageous when the topic has not previously been reviewed at length (Hidalgo Landa et al. 2011) . Furthermore, scoping reviews are utilised as standalone projects that provide widespread descriptive summaries of the literature, comprising of a broad range of study designs and methodologies (Arskey and O'Malley 2005; Brien et al. 2010) . Scoping reviews use meticulous and transparent methods to recognise and analyse literature relevant to a specific topic (Arskey and O'Malley 2005; Rumrill et al. 2010 ).
The present study adhered to a six stage method as developed by Arskey and O'Malley (2005) with advanced recommendations by Levac et al. (2010) . These stages included: (1) identifying the central research question, (2) searching for relevant studies, (3) selection of studies, (4) charting the data, (5) and collating, summarizing and reporting the results. The scoping study began with the formation of the research team including those with expertise in the areas of pharmacy, addiction, harm reduction; and scoping and systematic reviews (Levac et al. 2010) . The research team identified the underpinning research question: Bwhat do we know about cases of treatment of codeine dependence using buprenorphine-naloxone?^The review aimed to collect extant clinical case presentation literature on codeine dependence treatment using buprenorphine-naloxone.
A comprehensive list of search terms was devised by the team which combined the terms 'Codeine' with 'Buprenorphine-naloxone'; 'Suboxone ®'; and 'clinical case presentation'. To ensure all literature relevant to the present study were included; a comprehensive search was carried out using the following databases: Science Direct, EBSCO Host, PsychINFO, and PubMED. The initial search identified 5535 articles, and following exclusion of animal studies, duplicates, and lack of relevance specifically to the treatment of codeine with buprenorphine-naloxone, six case studies/series papers were identified to directly relate to the case presentations describing treatment of codeine dependence with buprenorphine-naloxone. We additionally scrutinised the bibliographies of studies identified in the literature search. This process discovered one further reference (n = 1) with no subsequent records identified (Arskey and O'Malley 2005) . A total of seven case presentation records (four single case studies and three case series) on codeine dependence treated with buprenorphine-naloxone were included in the review. See Fig. 1 .
Results
Case studies were conducted in Scotland (Conroy and Hill 2014; Marr and Hill 2015) , Wales (Hard 2014) , United Kingdom (Kean 2015) , Australia (Nielsen et al. 2015d, e) and Ireland (Van Hout et al. 2015c) . Details relating to the single case studies (Conroy and Hill 2014; Marr and Hill 2015; Hard 2014; Kean 2015) and the case series (Nielsen et al. 2015d, e, b; Van Hout et al. 2015c ) are presented in Table 1 . Five themes emerged following a review of the cases for the treatment of codeine dependence with buprenorphine-naloxone, as follows (1) 
Patient Profiles
Of the four single case studies, three patients were female with their ages ranging from early to mid-twenties (Conroy and Hill 2014; Hard 2014; Marr and Hill 2015) , with one male in his mid-thirties (Kean 2015) . The three case series consisted of 53 female and 23 male participants with an age range of 38 to 57 years (Nielsen et al. 2015d, e, b; Van Hout et al. 2015c ).
History of Codeine Misuse
Reasons for initiation to codeine use were: post-surgery pain (Conroy and Hill 2014) ; myalgic encephalopathy (Hard 2014) ; back pain (Kean 2015) ; dental pain (Marr and Hill 2015; Van Hout et al. 2015c ); pain relief not specified (n = 47); previous opioid dependence (n = 8) (Nielsen et al. 2015d, e, b) ; pain relief for a broken wrist; migraines (Van Hout et al. 2015c) , and reason not stated (n = 14) (Nielsen et al. 2015d ). Length of codeine use varied starting at two years (Marr and Hill 2015) , (Hard 2014) . Two studies (Nielsen et al. 2015d, e, b) did not specify the type of codeine medication used. Great variation in daily doses of codeine was evident beginning at 30 mg (Hard 2014) 180 mg (Conroy and Hill 2014) ; 240 mg (Kean 2015) ; 360 mg (Conroy and Hill 2014) ; 1205 mg (Kean 2015) ; and the highest dose was 2940 mg daily (Hard 2014) . One study (Nielsen et al. 2015c ) did not state dosage and another (Nielsen et al. 2015e ) stated a mean daily dosage of 564 mg. All studies reported misuse of prescribed codeine medications however two reported the use of diverted codeine medicines (Conroy and Hill 2014; Kean 2015) , one via street dealers (Conroy and Hill 2014 ) the other did not report where the diverted medicines were obtained (Kean 2015) .
Medical Problems
Medical complications arising from excessive and long term use of codeine containing products included: Addisons Disease; haematemesis; pancreatitis; and gastro-intestinal (GI) haemorrhage (Van Hout et al. 2015c) ; collapse (Conroy and Hill 2014) ; constipation (Marr and Hill 2015) ; withdrawal symptoms related to codeine dependence (Conroy and Hill 2014; Hard 2014; Kean 2015) . One study reported a series of mental health disorders: anxiety disorder (n = 14); bipolar disorder (n = 7); eating disorders (n = 2); depression (n = 31); psychiatric comorbidity (n = 42); post-traumatic stress disorder (PTSD) (n = 5); and schizophrenia (n = 3) (Nielsen et al. 2015d ).
Use of Other Substances
Other substances used concurrently with codeine by some of the patients were: nicotine (n = 24); stimulants (n = 3); cannabis (n = 5); problematic alcohol (n = 14); and benzodiazepines (n = 17) (Nielsen et al. 2015d) . Van Hout et al. (2015c) reported the use of hypnotics; tramadol; and cough medicines with codeine containing medications. Heroin use was reported as a replacement for di-hydrocodeine by one patient when a prescription for di-hydrocodeine was unavailable to her (Conroy and Hill 2014) and 7 other patients reported a previous history of heroin use (Nielsen et al. 2015d ). Three studies did not state any substances being used concurrently with codeine (Hard 2014; Kean 2015; Marr and Hill 2015) .
Buprenorphine-Naloxone in the Treatment of Codeine Dependence
Treatments other than and prior to treatment using buprenorphine-naloxone were methadone maintenance treatment (Conroy and Hill 2014; Nielsen et al. 2015d ) and previous episodes of treatment for addiction (Nielsen et al. 2015d) , however this was not reported in all studies. Length of treatment using buprenorphine-naloxone varied and was reported as: 1 month (Nielsen et al. 2015e ); 3 months (Van Hout et al. 2015c ) several months (Conroy and Hill 2014) , 6 months (Hard 2014; Kean 2015) ; and 11 months (Van Hout et al. 2015c ) in duration, but was not reported in some cases (Marr and Hill 2015; Nielsen et al. 2015d) . Doses ranged between 4 and 24 mg daily with tapering of doses reported: 24 to 16 mg (Conroy and Hill 2014) ; 16 to 10 mg (Hard 2014 ); 8 to 0 mg (Kean 2015) and 16 mg tapering 2 mg each month, stable on 8 mg at time of study (Marr and Hill 2015) . Van Hout et al. (2015c) reported dosages of between 4 and 14 mg per day. Median doses of 12 to 16 mg was reported by Nielsen et al. (2015b) . One study did not report dosage levels (Nielsen et al. 2015d) . One patient was reported as abstinent at the time of the case study (Kean 2015) and some patients were stabilised at the time of writing the paper (Conroy and Hill 2014; Hard 2014; Marr and Hill 2015; Van Hout et al. 2015c ) however this factor was not reported on all cases (Nielsen et al. 2015d, e, b) .
Psychosocial treatments reported were: treatment for anxiety, peer mentoring, 12 step fellowship (Hard 2014) ; Social Behaviour and network Therapy (Kean 2015) ; CBT (Hard 2014; Kean 2015) ; and counselling (Van Hout et al. 2015c) . One study reported psychosocial treatment was part of the process but no detail was given on which type of treatment (Conroy and Hill 2014) .
Discussion
We present here a review of available case literature on the use of buprenorphinenaloxone in the treatment of codeine dependence. The seven case presentation (single and series) papers highlight the growing number of presentations where codeine is the primary drug of misuse and dependence. The wide range of people who become dependent on OTC codeine combination analgesics range from those with a history of complex and multiple addictions, personality and psychological difficulties to those where initial consumption of codeine occurred to treat legitimate pathology (Van Hout et al. 2015c ). The issue of iatrogenic opioid analgesic dependence confounds treatment pathways and recovery outcomes (Stannard 2013; Marr and Hill 2015) . Therefore, distinguishing between iatrogenic opioid dependence and that of misuse and problematic use leading to dependence is essential in facilitating enhanced treatment, particularly for pain patients (Marr and Hill 2015) . The need for prescriber and pharmacist assessment of risk for codeine dependence through initial and ongoing routine screening is argued for (Bergin et al. 2015; Hard 2014; Van Hout et al. 2015c . Of note was the high dose consumption of these codeine containing products, where recommended adult daily oral doses of codeine range between 30 and 60 mg every 4 h and to a maximum of 240 mg (Derry et al. 2013) .
Codeine dependent user demographics are different when compared to other strong prescription opioid dependent users, and pointing to the widening of patient access to buprenorphine naloxone as a low threshold treatment option (Nielsen et al. , 2015c . Buprenorphine-naloxone treatment is more common for codeine dependent users than methadone, as it favours those who socially function well and wish to remain at work, thereby, reducing the potential for stigma and restrictive aspects often associated with methadone (Nielsen et al. 2015b; Van Hout et al. 2015c ). The potential of effective opioid assisted treatment using buprenorphine naloxone with psychosocial interventions/counselling to treat this form of opioid dependence is gaining support from both clinicians (Conroy and Hill 2014; Hard 2014; Kean 2015) and codeine dependent users themselves (Van Hout et al. 2015a, b) . The codeine dependent cases reviewed here highlights a more favourable response to treatment consisting of the use of buprenorphine-naloxone within a biopsychosocial approach, thereby creating for more positive recovery outcomes for individuals underpinned by enhanced social and occupational functioning.
In terms of dose titrations, codeine is of lower potency than many other opioids with codeine dependent individuals using lower doses of opioids when compared to oral morphine equivalents (Nielsen et al. 2015c ). The Australian case series demonstrated that codeine dependent users were receiving higher sublingual buprenorphine doses than when calculated against the dose of codeine consumed and were similar to that of other service users being treated for heroin dependence or more potent opioids (Nielsen et al. 2015b ). This suggests that clinicians using standard opioid conversion calculations (Fine et al. 2009 ) are at risk of underestimating the buprenorphinenaloxone dose that codeine dependent users actually require resulting in poorer clinical outcomes, and also, suggesting that high doses of buprenorphine-naloxone (up to 32 mg daily) appears well tolerated by this group of codeine dependent users (Nielsen et al. 2015b) . While individual dose titration is best practice (Gowing et al. 2014 ) a recommendation that codeine dependent individuals receive similar doses to that of other opioid dependents is suggested (Nielsen et al. 2012) , thereby improving treatment retention (Fareed et al. 2012 ).
Conclusion
A scoping review presented the clinical case presentation (single and series) literature in relation to the use of buprenorphine-naloxone in the treatment of codeine dependence. Findings illustrate the complexities of these distinct opiate dependent patients with regards to pain, psychiatric illness, poly substance use and iatrogenic dependence. Given this distinct form of opioid dependence, buprenorphine-naloxone as treatment modality is encouraging in terms of patient stabilisation and recovery, and warrants expansion of access within low threshold treatment service design. Further research is warranted to explore how the various treatment approaches (buprenorphine-naloxone and psychosocial interventions) influence long term outcomes for this unique cohort of codeine dependent individuals.
